They own about the same as Ponce (30% or so), there was an old bloomberg article (a few months ago) regarding Potash and potential acquisition of SQM. You should search for it if you are interested, think Potash acquiring SQM bloomberg should bring it up. Basically Ponce is in some financial trouble and had to raise capital from other holdings. Rumor is he may be forced to sell if continued weakness in pricing.
I thought the last comments on yesterday's release was strange, yet very interesting.
Looking forward to hear CC tomorrow.
I did research when I first bought, and with the current bylaws, it would be very difficult to acquire everything (but I am no lawyer).
My advice always has been with this stock, either you are long term or you shouldn't own. While buyout is possible, I think SQM is just a value to hold given their assets and low cost provider. Tesla just made the move to bring Lithium into the next mega cycle, knew it would happen one day, but thanks to him a little earlier than the 2020 I thought.
#$%$ are you talking about, he asked a specific question today how many people are happy with performance in the last year.....so I just pulled the 1 year chart. I didn't pick a specific day.
Granted all dependent on Otrexup launch and traction later this year. But still believe pipeline undervalued. If you are a long term investor, I still think $7 is in the future (maybe 2016).
BTW I have held over a year.
Thanks for reminding me why I don't ever post on YMB.
Can't believe I am actually responding to this.
$3.36 as of 2/26/13, now $4.61- gain of 37.2% outperforming the 20% or so gain from S&P from same time frame.
I will take a 20+ point out performance vs. S&P any year.
So you obviously don't know EU process of approval.
CHMP recommendation will be either January or February (likely February). Then 3 or 4 months will get marketing approval.
Look at Herceptin SC as example, 14 months from file to CHMP positive recommendation, 4 months from CHMP to marketing approval.
There is no change to this guidance.
So could have FDA approval of Hyqvia and Mabthera SC approval around mid year. Which means 2nd half launch. Probably will get milestone payments, but not much revenues this year.
Sentiment: Strong Buy
Far enough for what? Check Fezz's catalyst list
I am long 2000 shares and been rolling over calls since last ASCO (up to 130 contracts with variety of strikes/dates). I would do the same until more mature PEGPH20 data comes out. If it performs as early trials indicate, HALO will be $45+ stock in no time. I come up with $2B value of pipeline today without PEGPH20. It is the mother load, I just don't know when, will it be prelim data at ASCO in June or when final data is available early next year or will it be a partnership tomorrow? Time will tell but I am long for at least two years. Will continue coverting calls to shares and continuing to roll over my calls, this thing will double sometime in the next 18 months and I will be in it when it does. Classic case of huge pipeline and wall street isn't valuing the sum of parts, however over the last 6 months they have caught on a bit.
Sentiment: Strong Buy